Alitretinoin Cuts Chronic Hand Eczema Severity

This article originally appeared here.
Share this content:
Alitretinoin Cuts Chronic Hand Eczema Severity
Alitretinoin Cuts Chronic Hand Eczema Severity

THURSDAY, Aug. 11, 2016 (HealthDay News) -- Alitretinoin treatment aids in normalizing expression of barrier genes and proteins in patients with chronic hand eczema (CHE), according to a study published online Aug. 2 in the British Journal of Dermatology.

Vandana Kumari, Ph.D., from Charit é Universitätsmedizin Berlin, and colleagues assessed the effect of 30 mg/day of alitretinoin on 15 patients with CHE treated for up to 27 weeks. Disease severity was measured with a clinical score. Skin biopsies were analyzed before and after therapy for the expression of Ki-67, various skin barrier genes, and thymic stromal lymphopoietin using quantitative polymerase chain reaction and immunohistochemistry.

The researchers found that the majority of patients had improvement in clinical severity with alitretinoin treatment. There was a significant increase in Ki-67-positive cells in the suprabasal layer and a dysregulated expression of various skin barrier genes (claudin 1, loricrin, filaggrin and cytokeratin 10) seen in skin biopsies before treatment, which normalized after treatment. Thymic stromal lymphopoietin was significantly upregulated, but also normalized after treatment.

"The change in expression levels of these genes correlated with the clinical efficacy, suggesting that alitretinoin exhibits a disease-modifying activity," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »